LEQEMBITM Infusion Therapy
About LEQEMBITM Infusion Therapy
Beta-amyloid proteins collect and form plaques between neurons of the brain. The plaques affect brain and memory function. While LEQEMBI does not improve symptoms of Alzheimer’s, it can slow disease progression and prolong mental functioning.
LEQEMBI for Alzheimer’s
LEQEMBI is the second in a class of new medications developed to slow disease progression and cognitive decline of patients with Alzheimer’s disease. Memory, including the ability to remember important dates, events, and conversations, and thinking and judgment skills may be maintained longer for patients receiving LEQEMBI infusion therapy.
In a phase 3 clinical trial of 1,795 participants, LEQEMBI patients’ clinical decline slowed by 27% after receiving treatment for 18 months.
What to Expect During LEQEMBI Infusion Therapy
LEQEMBI infusion patients require an MRI before their first treatment to evaluate for pre-existing amyloid-related imaging abnormalities (ARIA) and again after their 5th, 7th, and 14th infusions. ARIAs may develop in rare cases while receiving LEQEMBI infusion therapy. Most occurrences are asymptomatic and resolve on their own.
While uncommon, some patients may experience mild infusion reactions (fever and flu-like symptoms, nausea, vomiting, hypotension, hypertension, and oxygen desaturation). Premedications, including antihistamines, acetaminophen, NSAIDs, or corticosteroids may be used to prevent symptoms of infusion reactions.
Your comfort during LEQEMBI infusion therapy at FlexCare is our priority. Our LEQEMBI patients enjoy private infusion suites, walk-up parking, and complimentary entertainment and snacks during each infusion. Plus, FlexCare’s evening and weekend hours and convenient city and rural locations make it easier to schedule your appointments.
Getting Started With Infusion Therapy
If you have any questions, you can also contact FlexCare directly. We look forward to helping you soon.